Impact of New Hematopoietic Progenitor Cell Collection Goals on Apheresis and Cell Therapy Laboratory Services
Fuente:
Wiley Open Access
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Artículo Open Access |
| Publicado: |
Wiley
2025
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1867016398216101888 |
|---|---|
| author | Aaron J. Wyble V. Rakesh Sethapati Steven R. Post Haley McAloon Nancy Green Mayumi Nakagawa Michele Cottler‐Fox Gina Drobena |
| author_facet | Aaron J. Wyble V. Rakesh Sethapati Steven R. Post Haley McAloon Nancy Green Mayumi Nakagawa Michele Cottler‐Fox Gina Drobena Aaron J. Wyble V. Rakesh Sethapati Steven R. Post Haley McAloon Nancy Green Mayumi Nakagawa Michele Cottler‐Fox Gina Drobena |
| collection | Wiley Open Access |
| contents | Impact of New Hematopoietic Progenitor Cell Collection Goals on Apheresis and Cell Therapy Laboratory Services Aaron J. Wyble V. Rakesh Sethapati Steven R. Post Haley McAloon Nancy Green Mayumi Nakagawa Michele Cottler‐Fox Gina Drobena Journal of Clinical Apheresis ABSTRACTIn order to reflect patient needs given new treatment options for hematopoietic malignancies, autologous hematopoietic progenitor cell (HPC) collection goals were changed to 10 or 15 × 106 CD34+/kg (previously 20 × 106 CD34+/kg) for myeloma patients and to 5 × 106 CD34+/kg (previously 10 × 106 CD34+/kg) for lymphoma patients in March 2023. The minimum number of large volume leukapheresis (LVL) procedures required decreased from two to one. We analyzed the impact of these changes on apheresis and cell therapy laboratory (CTL) services. Data from the post‐implementation period of April through December in 2023 were compared to those from the same 9‐month periods in 2022 and 2021 as controls. The number of patients undergoing autologous HPC collection per month were examined. The numbers of LVL procedures, numbers of cryopreserved bags, and apheresis and CTL staffing hours and costs were determined retrospectively on a per patient and monthly basis. One‐way ANOVA with Tukey's multiple comparison was performed. The per patient averages for LVL procedures, cryopreserved bags, staff hours, and costs in apheresis and CTL services were decreased significantly in 2023 compared to both control periods. However, for monthly analyses, differences were significant between 2023 and 2021; but not between 2023 and 2022. No differences were seen between the two control periods. The changes in autologous HPC collection goals led to a significant decrease in LVL procedures and cryopreserved bags required per patient to meet collection goals, reducing costs and workload for apheresis and CTL. 10.1002/jca.70048 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| doi_str_mv | 10.1002/jca.70048 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_jca_70048 |
| institution | Wiley Open Access |
| license_str_mv | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| publishDate | 2025 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Impact of New Hematopoietic Progenitor Cell Collection Goals on Apheresis and Cell Therapy Laboratory Services Aaron J. Wyble V. Rakesh Sethapati Steven R. Post Haley McAloon Nancy Green Mayumi Nakagawa Michele Cottler‐Fox Gina Drobena Journal of Clinical Apheresis Impact of New Hematopoietic Progenitor Cell Collection Goals on Apheresis and Cell Therapy Laboratory Services Aaron J. Wyble V. Rakesh Sethapati Steven R. Post Haley McAloon Nancy Green Mayumi Nakagawa Michele Cottler‐Fox Gina Drobena Journal of Clinical Apheresis ABSTRACTIn order to reflect patient needs given new treatment options for hematopoietic malignancies, autologous hematopoietic progenitor cell (HPC) collection goals were changed to 10 or 15 × 106 CD34+/kg (previously 20 × 106 CD34+/kg) for myeloma patients and to 5 × 106 CD34+/kg (previously 10 × 106 CD34+/kg) for lymphoma patients in March 2023. The minimum number of large volume leukapheresis (LVL) procedures required decreased from two to one. We analyzed the impact of these changes on apheresis and cell therapy laboratory (CTL) services. Data from the post‐implementation period of April through December in 2023 were compared to those from the same 9‐month periods in 2022 and 2021 as controls. The number of patients undergoing autologous HPC collection per month were examined. The numbers of LVL procedures, numbers of cryopreserved bags, and apheresis and CTL staffing hours and costs were determined retrospectively on a per patient and monthly basis. One‐way ANOVA with Tukey's multiple comparison was performed. The per patient averages for LVL procedures, cryopreserved bags, staff hours, and costs in apheresis and CTL services were decreased significantly in 2023 compared to both control periods. However, for monthly analyses, differences were significant between 2023 and 2021; but not between 2023 and 2022. No differences were seen between the two control periods. The changes in autologous HPC collection goals led to a significant decrease in LVL procedures and cryopreserved bags required per patient to meet collection goals, reducing costs and workload for apheresis and CTL. 10.1002/jca.70048 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| title | Impact of New Hematopoietic Progenitor Cell Collection Goals on Apheresis and Cell Therapy Laboratory Services |
| topic | Journal of Clinical Apheresis |
| url | https://onlinelibrary.wiley.com/doi/10.1002/jca.70048 |